Afficher la notice abrégée

dc.contributor.authorRiquelme Gallego, Blanca 
dc.contributor.authorGarcía Molina, Laura 
dc.contributor.authorCano Ibáñez, Naomi 
dc.contributor.authorAndújar Vera, Francisco Luis
dc.contributor.authorGonzález Salvatierra, Sheila
dc.contributor.authorGarcía Fontana, Cristina 
dc.contributor.authorBueno Cavanillas, Aurora 
dc.contributor.authorMuñoz Torres, Manuel Eduardo 
dc.contributor.authorGarcía Fontana, Beatriz 
dc.date.accessioned2022-09-07T09:23:56Z
dc.date.available2022-09-07T09:23:56Z
dc.date.issued2022-07-21
dc.identifier.citationRiquelme-Gallego, B... [et al.]. Undercarboxylated Osteocalcin: A Promising Target for Early Diagnosis of Cardiovascular and Glycemic Disorders in Patients with Metabolic Syndrome: A Pilot Study. Nutrients 2022, 14, 2991. [https://doi.org/10.3390/nu14142991]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/76564
dc.description.abstractLifestyle changes are causing an exponential increase in the prevalence of obesity and metabolic syndrome (MetS) worldwide. The most frequent complications of these are the development of diabetes (T2D) and cardiovascular disease (CVD). Accurate tools are needed to classify the cardiovascular risk (CVR) in the MetS population. In recent years, numerous biomarkers of bone metabolism have been associated with CVR. The aim of this study was to determine the levels of undercarboxylated osteocalcin (ucOC) in a cohort of patients with MetS and to analyse its association with MetS parameters and CVR as well as with T2D prevalence. A longitudinal study was conducted in which a MetS population was followed for one year. Weight change, adherence to the Mediterranean diet (MedDiet), ucOC levels, MetS parameters and CVR were analysed and CVR was calculated using different scores. Our results showed a decrease of CVR associated with a better adherence to the MetDiet resulting in higher HDL-C and ucOC levels though the improvement of MetS risk factors. This bone protein appeared as a potential biomarker to classify CVR in the MetS population, especially for MetS patients without prevalent T2D. Furthermore, ucOC serum levels could be good predictors of T2D prevalence.es_ES
dc.description.sponsorshipInstituto de Salud Carlos III European Commission PI18-00803 PI21/01069 PI18-01235 FI19/00118 CD20/00022es_ES
dc.description.sponsorshipEuropean Commissiones_ES
dc.description.sponsorshipJunta de Andalucia CD20/00022 PI-0268-2019 RH-00692021es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectMetabolic syndromees_ES
dc.subjectCardiovascular riskes_ES
dc.subjectDiabetes es_ES
dc.subjectOsteocalcines_ES
dc.subjectMediterranean dietes_ES
dc.titleUndercarboxylated Osteocalcin: A Promising Target for Early Diagnosis of Cardiovascular and Glycemic Disorders in Patients with Metabolic Syndrome: A Pilot Studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/nu14142991
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Fichier(s) constituant ce document

[PDF]

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Atribución 4.0 Internacional
Excepté là où spécifié autrement, la license de ce document est décrite en tant que Atribución 4.0 Internacional